摘要
目的探讨免疫检查点B7-H3、跨膜和免疫球蛋白结构域2(TMIGD2)、人内源性逆转录病毒-H长末端重复关联蛋白2(HHLA2)在卵巢癌中的表达及临床意义。方法选取84例卵巢癌患者为研究对象,检测患者治疗前后血清B7-H3水平,以及癌组织B7-H3、TMIGD2、HHLA2蛋白表达情况。采用logistic回归分析组织B7-H3、TMIGD2、HHLA2蛋白表达与卵巢癌不同病理特征的关系。结果卵巢癌患者治疗后血清B7-H3水平低于治疗前(P<0.05);不同FIGO分期、肿瘤大小及是否出现淋巴结转移、腹腔积液的卵巢癌患者血清B7-H3水平比较,差异具有统计学意义(P<0.05)。卵巢癌组织B7-H3、TMIGD2、HHLA2蛋白阳性表达分别为67例(79.8%)、55例(65.5%)、56例(66.7%)。不同FIGO分期、是否存在腹腔积液的卵巢癌患者癌组织B7-H3表达比较,差异具有统计学意义(P<0.05);不同FIGO分期、肿瘤大小及是否存在淋巴结转移、腹腔积液卵巢癌患者组织TMIGD2、HHLA2表达比较,差异具有统计学意义(P<0.05)。结论免疫检查点B7-H3、TMIGD2、HHLA2的表达与卵巢癌患者病情进展相关,可作为卵巢癌治疗及预测的新靶点。
Objective To investigate the expression and clinical significance of immune checkpoint B7-H3,transmembrane and immunoglobulin domain 2(TMIGD2)and human endogenous retrovirus-H long terminal repeat-associated protein 2(HHLA2)in patients with ovarian cancer.Methods 84 patients with ovarian cancer were selected.Serum B7-H3 levels and B7-H3,TMIGD2 and HHLA2 protein expression in cancer tissues were measured before and after treatment.The relationship between tissue B7-H3,TMIGD2,and HHLA2 protein expressions and different pathological characteristics of ovarian cancer was analyzed by logistic regression.Results The serum B7-H3 level of ovarian cancer patients after treatment was lower than that before treatment(P<0.05).There were significant differences in serum B7-H3 levels among ovarian cancer patients with different FIGO stages,tumor sizes and the presence of lymph node metastasis,and peritoneal effusion(P<0.05).The positive expression of B7-H3,TMIGD2,and HHLA2 protein in ovarian cancer tissues was 67(79.8%),55(65.5%),and 56(66.7%),respectively.There was a significant difference in B7-H3 expression in the tissues of ovarian cancer patients with different FIGO stages and the presence of peritoneal effusion(P<0.05).There were significant differences in TMIGD2 and HHLA2 expression in tissues of ovarian cancer patients with different FIGO stages,tumor sizes and the presence of lymph node metastasis,and peritoneal effusion(P<0.05).Conclusion The expressions of immune checkpoints B7-H3,TMIGD2 and HHLA2 are correlated with the progression of ovarian cancer and can be used as new targets for the treatment and prediction of ovarian cancer.
作者
张娟
孙丽莎
王虹
ZHANG Juan;SUN Lisa;WANG Hong(Jiaozuo Second People's Hospital,Jiaozuo,454100)
出处
《实用癌症杂志》
2022年第9期1415-1419,共5页
The Practical Journal of Cancer
